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Affordable next-generation sequencing (NGS) technologies for hepatitis C virus (HCV)may potentially identify both viral geno-
type and resistance genetic motifs in the era of directly acting antiviral (DAA) therapies. This study compared the ability of high-
throughput NGSmethods to generate full-length, deep, HCV sequence data sets and evaluated their utility for diagnostics and
clinical assessment. NGSmethods using (i) unselected HCV RNA (metagenomics), (ii) preenrichment of HCV RNA by probe
capture, and (iii) HCV preamplification by PCR implemented in four United Kingdom centers were compared. Metrics of se-
quence coverage and depth, quasispecies diversity, and detection of DAA resistance-associated variants (RAVs), mixed HCV ge-
notypes, and other coinfections were compared using a panel of samples with different viral loads, genotypes, andmixed HCV
genotypes/subtypes [geno(sub)types]. Each NGSmethod generated near-complete genome sequences frommore than 90% of
samples. Enrichment methods and PCR preamplification generated greater sequence depth and were more effective for samples
with low viral loads. All NGSmethodologies accurately identified mixed HCV genotype infections. Consensus sequences gener-
ated by different NGSmethods were generally concordant, andmajority RAVs were consistently detected. However, methods
differed in their ability to detect minor populations of RAVs. Metagenomic methods identified human pegivirus coinfections.
NGS provided a rapid, inexpensive method for generating whole HCV genomes to define infecting genotypes, RAVs, comprehen-
sive viral strain analysis, and quasispecies diversity. Enrichment methods are particularly suited for high-throughput analysis
while providing the genotype and information on potential DAA resistance.
Hepatitis C virus (HCV) chronically infectsmore than 150mil-lion people globally and is associatedwith the development of
liver fibrosis, cirrhosis, hepatic failure, and hepatocellular cancer
(1). Historically, treatment of HCV has been based on interferon
alpha (IFN-) and ribavirin (RBV), which are associated with
high treatment failure rates and severe side effects. New all-oral
directly acting antivirals (DAAs) with high efficacy rates and an
improved safety profile have recently revolutionized the treat-
ment ofHCV.Most recently, oral therapies that targetNS3,NS5A,
and NS5B HCV proteins have been approved by the Food and
Drug Administration and EuropeanMedicines Agency regulatory
bodies (2, 3) and, used in combination, these DAAs achieve high
sustained virological response (SVR) rates with minimal side ef-
fects (4). HCV is currently classified into seven major genotypes
and 67 subtypes (5). At present, there is no truly pan-genotypic
DAA treatment regimen with both drug choice and treatment
duration defined by the viral genotype. Genotype 3 in particular
appears less susceptible to DAA therapies (6). Therefore, the ac-
curate assignment of viral genotype and subtype remains an im-
portant stratification parameter both in clinical trials of DAA
therapy and in clinical practice.
Although a minority of patients fail to achieve SVR with
all-oral combination therapy, failure more commonly occurs
in patients with advanced liver disease, and optimal retreat-
ment strategies in all patients who fail DAA therapies are cur-
rently unclear. Initially, it was reported that treatment failure
with combination DAAs was rarely associated with the devel-
opment of viral resistance-associated variants (RAVs), and
therefore, the role for the development of sequencing technol-
ogies or phenotypic characterization to assess RAVs was un-
clear. However, with the exception of the NS5B inhibitors, each
of the DAAs is known to have a low genetic barrier for the
development of antiviral resistance, and naturally occurring
HCV polymorphisms may confer DAA resistance. Currently,
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prescreening for RAVs prior to treatment is recommended
only for the NS3 protease inhibitor simeprevir (7), since the
Q80K mutation that can confer resistance is widely distributed
among genotype 1a variants. However, while simeprevir may
soon become obsolete in HCV treatment strategies, careful
analysis of viral sequences by independent investigators has
revealed that RAVs may emerge in association with DAA treat-
ment failure even with the high barrier to resistance NS5B in-
hibitors (8). The emergence of resistance to DAAs targeting
NS5A is clearly documented and of particular concern as these
do not incur a significant fitness cost for replication. They can
persist and transmit in the community (9).
Currently, the assessment of viral genotype commonly uses
probe-based assays that target the highly conserved 5= untrans-
lated region (5=UTR), while the detection of RAVs currently relies
upon the targeted analysis of genomic regions that rely on PCR
Sanger sequencing; the application of this method is limited by
problemswith primer design for highly divergentHCVgenotypes,
genome coverage, and a restricted and inconsistent ability to de-
tect both minor populations of RAVs as well as mixed-genotype/
subtype [geno(sub)type] infections that may be relevant for treat-
ment response. We therefore developed and compared next-
generation sequencing (NGS) technologies for the generation of
full-lengthHCV sequences, with the potential to accurately define
HCV geno(sub)type while also simultaneously identifying both
RAV and minor variant populations across the entire genome.
Whole-genome sequencing (WGS) that could be routinely ap-
plied in clinical practice could inform retreatment strategies and
also provide more-detailed sequence data to examine transmis-
sion events between individuals and potentially inform public
health intervention strategies. Together, these capabilities would
represent a major advance in the field.
We evaluated and compared three approaches across four
United Kingdom laboratories in order to establish the robustness
of pipelines for sequencingHCVRNA fromplasma. The simplest,
“metagenomic” approach obtains data that is unbiased by infect-
ing genotype, with the potential benefit of detecting additional
pathogens but with the substantial disadvantage that the vast ma-
jority of sequence reads obtained are of human origin and are
discarded. “Enrichment” approaches provide an alternative in
whichHCV sequences are targeted for capture frommetagenomic
sequencing libraries using panels of oligonucleotide probes but at
the expense of missing nontargeted pathogens and, potentially,
divergent HCV sequences. Both techniques were compared with
an approach in which the HCV genome is spanned by six overlap-
ping PCR amplicons which are pooled and sequenced to a high
depth by NGS.
In evaluating the effectiveness of metagenomic, enrichment,
and PCR amplification approaches to HCV whole-genome se-
quencing, we compared data generated using a variety of proto-
cols at different laboratory sites and so explored the reproducibil-
ity of aspects of the sequence data in independent trials, including
the generation of accurate consensus sequences, detection of qua-
sispecies diversity, and full sequence coverage of the HCV ge-
nome. The analysis allowed us to define a relationship between
sequencing depth and coverage with RNA viral loads and so pre-
dict the expected success rates for clinical samples. Finally, we
explored the reproducibility of recovery of virus subpopulations
and minor variants, using panels of mixed samples and DAA-
associated polymorphisms.
MATERIALS AND METHODS
Samples. A range of plasma samples, assay controls, and in vitro tran-
scripts were used to evaluate NGS methods. These samples included the
following.
(i) Plasma samples. Plasma samples from individuals infected with
HCVgenotypes 1a, 1b, 2, 3, and 4were obtained from theHCVResearchUK
Biobank (http://www.hcvresearchuk.org/). Samples were used with in-
formed consent conforming to the ethical guidelines of the 1975 Declara-
tion of Helsinki, and study protocols were approved by the National Re-
search Ethics Service (NRES) Committee East Midlands (reference 11/
EM/0323). Viral loads (VLs) were measured by COBAS TaqMan PCR
(Roche) according to the manufacturer’s protocol. Viral loads were ex-
pressed as international units (IU) per milliliter.
(ii) Mixed-genotype plasma samples. Two samples from the United
Kingdom Quality Control for Molecular Diagnostics (QCMD) HCV ge-
notype panel containing mixed genotypes (HCVG10-02 [genotypes 1b
and 3a] and HCVG10-04 [genotypes 3a and 5a]) were used. Artificial
mixtures of plasma samples fromHCV Research UK containing different
geno(sub)types were created in defined ratios using viral loads measured
by COBAS TaqMan PCR (see Table S1B in the supplemental material).
(iii) In vitro RNA transcripts. Full-length cDNA clones of the HCV
strains H77 and JFH-1 were linearized with XbaI, treated withmung bean
nuclease (New England BioLabs) to remove 5=-end overhangs and puri-
fied (PureLink PCR purification kit; Invitrogen). One microgram of lin-
earized DNA template was used for RNA transcription using T7 RNA
polymerase (MEGAscript; Ambion) for 1 h at 37°C. RNA was cleaned up
using the RNeasy kit (Qiagen), and the integrity of the RNA was analyzed
by nondenaturing agarose gel electrophoresis. RNA concentrations were
determined using spectrophotometry. Transcripts were diluted in Tris-
EDTA (TE) buffer and mixed in ratios at known concentrations before
distribution to the four laboratories (see Table S1B in the supplemental
material).
Together these samples were used to create the NGS evaluation panel.
This panel comprised the following: (i) plasma samples from 27 individ-
uals infected with single genotypes as determined by the referring labora-
tories and a negative control (see Table S1A in the supplementalmaterial);
(ii) seven samples containing a mixture of two samples of known geno-
types spanning genotypes 1, 2, 3, and 4 (Table S1B); (iii) nine samples
containing RNA transcripts from genotype 1a and 2a in ratios corre-
sponding to 5,000:1 to 1:5,000 of genotype 1a and 2a in vitro RNA tran-
scripts (IVTs), respectively.
Sequencing methods. (i) Summary. The combined evaluation panel
of 43 samples was used to evaluate the performance of seven sequencing
methods developed at four expert centers in the United Kingdom. The
four expert centers were Glasgow (G), Oxford (O), PublicHealth England
(PHE [P]), and University College London (UCL [U]) and are indicated
by the letters before the method. Each sample was assayed in a blind
manner using NGS platforms and either unselected (metagenomic) ap-
proaches (G-Meta andO-Meta), probe-basedHCV sequence enrichment
(G-SSel, G-Nimb, O-Capt, and U-Capt), or HCV-specific PCR amplifi-
cation and sequencing (P-PCR) (methods and method codes given in
Table 1). Data from each method were processed using analysis pipelines
established at each center (Table 1). Processing of read data consensus
sequence construction, assessment of genome coverage, and accuracy
and quantification of quasispecies diversity used a common set of tools
in an additional center that coordinated the analysis (Edinburgh,
United Kingdom).
(ii)O-Meta andO-Capt.Total RNAwas extracted from500l plasma
using theNucliSENSmagnetic extraction system (bioMérieux) and eluted
into 30 l of kit buffer. Metagenomic libraries were prepared using the
NEBNext Ultra Directional RNA Library Prep kit for Illumina (New Eng-
land BioLabs); 5 l (maximum, 10 ng) of RNA was fragmented (5 or 12
min at 94°C), reverse transcribed, amplified (5 to 18 PCR cycles) using
indexed primers, and then purified into 0.85 volumeAmpureXP (Beck-
man Coulter). Libraries were quantified (Quant-iT PicoGreen dsDNA
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[double-stranded DNA] assay kit; Invitrogen) and assessed for purity
(TapeStation with D1K High Sensitivity kit; Agilent) before pooling in
equimolar proportions and final normalization (KAPA SYBR Fast qPCR
[quantitative PCR] kit; KAPA Biosystems). Metagenomic virus RNA se-
quencing (RNA-Seq) libraries were sequenced with 100-base paired-end
(PE) reads on the Illumina HiSeq 2500 sequencing system with v3 rapid
chemistry.
For capture, a 500-ng aliquot of the pooled O-Meta library was en-
riched using equimolar, pooled 120-nucleotide (nt) DNAoligonucleotide
probes (10) using the xGen Lockdown protocol from Integrated DNA
Technologies (IDT). Enriched pools were reamplified (12 cycles on-bead
PCR), repurified, and normalized using qPCR, and 100-base PE reads
were sequenced on a single run of the Illumina MiSeq system (v2 chem-
istry).
(iii) G-Meta and G-Capt. RNA was extracted from 200 l plasma
using the Agencourt RNAdvance blood kit (BeckmanCoulter) eluted into
11l of water and then reverse transcribed using Superscript III (Invitro-
gen) with randomhexamers and aNEB Second Strand Synthesis kit (New
England BioLabs) for library preparation using the KAPALibrary Prep kit
(KAPA Biosystems) with index tagging by 16 cycles of PCR using KAPA
HiFiHotStart (KAPABiosystems) andNEBNextMultiplexOligos (oligo-
nucleotides) for Illumina Index Primer Sets 1 and 2 (New England Bio-
Labs). Libraries were quantified by Qubit (ThermoFisher) and Tape-
Station (Agilent) and pooled at equimolar concentrations for sequencing
on the Illumina MiSeq platform (v3 chemistry).
For capture, pooled G_meta libraries were enriched by either the
NimbleGen SeqCap EZ system (Roche) (G_Nimb) or the SureSelect Tar-
get Enrichment system (Agilent) (G_SSel), the latter with double-scale
reactions and hybridization for 36 h rather than the recommended 16 to
24 h, and then sequenced on the IlluminaMiSeq platform using v3 chem-
istry (Illumina).
(iv) U-Capt. RNAwas extracted (QIAamp viral RNAminikit [catalog
no. 52904; Qiagen]) from 140 l of plasma eluted into 60 l of AVE
buffer, RNA was concentrated to 10 l by using either a Speedy-vac at
65°C or RNeasyMinElute Cleanup kit before first-strand cDNA synthesis
(Superscript III reverse transcriptase kit; Life Technologies).
Second-strand cDNA synthesis used 20 l from first-stand synthesis
(Second Strand cDNA synthesis kit; NEB). SureSelectXT Target Enrich-
ment (Agilent) was used for library preparation, hybridization, and en-
richment. A total of 120-mer RNA baits spanning 953 GenBank HCV
reference genomeswere designed by the PATHSEEK consortiumand syn-
thesized by Agilent Technologies. Purified double-stranded cDNA (ds
cDNA) was quantified (Qubit dsDNA HS assay kit; Life Technologies)
and sheared (200 to 500 ng ds cDNA for 150 s using Covaris E220 focused
ultrasonication system). Samples containing 200 ng were bulked with
human genomic DNA (gDNA) (Promega) prior to shearing. End repair,
adapter ligation, hybridization, PCR pre- and postcapture, and all post-
reaction cleanup steps were performed according to the SureSelectXT
Automated Target Enrichment for Illumina Paired-End Multiplexed
Sequencing 200 ng protocol (version F.2) on the Bravo platform Work-
Station B from Agilent Technologies. All recommended quality control
steps were performed on the 2200 TapeStation (Agilent Technologies).
The samples were sequenced on an Illumina MiSeq sequencing platform
with 500-bp v2 reagent sets. Base calling, adapter trimming, and sample
demultiplexing were generated as standard producing paired FASTQ files
for each sample.
(v) P-PCR. Viral RNA was extracted from 200 l plasma (Qiagen
Ultra Sens extraction kit). HCV genotype was defined using a pan-geno-
typic sequencing assay of the NS5B region as previously described (11).
Whole-genome sequencing used HCV genotype-specific primers in five
or six overlapping amplicons for each genotype/subtype (see Table S2 in
the supplemental material). Viral RNA was amplified (single-step reverse
transcription-PCR [RT-PCR]; Superscript III reverse transcriptase [Invit-
rogen]), followed by nested or seminested PCR. PCR products were pu-
rified (QIAquick kit; Qiagen) and quantified (Qubit dsDNA Broad Range
and High Sensitivity Assay kits and the Qubit 2.0 fluorometer; Life Tech-
nologies). Alternate amplicons were pooled in two reaction mixtures of
equimolar amounts, and 1 ng/l of the pooled DNA was used for library
preparation (Nextera XT DNA sample preparation kit; Illumina) accord-
ing to the manufacturer’s instructions. Indexed libraries were sequenced
using Illumina MiSeq deep sequencing reagent kit v2 (Illumina).
For quality assurance of primers used for amplification, the primers
TABLE 1 Sequencing methods and analysis pipelines evaluated at each sequencing center in the United Kingdom
Center Method Method code Sequencing method Analysis strategy
Oxford Metagenomic O-Meta Illumina RNA-Seq of total plasma RNA Bespoke bioinformatic pipeline to infer metagenomic,
consensus, and subpopulation level informationa
IDT O-Capt Genotype-specific HCV capture using IDT probes,
followed by Illumina RNA-Seqa
Bespoke bioinformatic pipeline to infer metagenomic,
consensus, and subpopulation level informationa
Glasgow Metagenomic G-Meta Illumina RNA-Seq of total plasma RNA FastQC, Tanoti,b in-house resistance mutation tools,
de novo assembly using MetAmos
SureSelect G-Ssel Genotype-specific HCV capture using SureSelect
DNA probes, followed by Illumina RNA-Seq
FastQC, Tanoti, in-house resistance mutation tools,
de novo assembly using MetAmos
NimbleGen G-Nimb Genotype-specific HCV capture using NimbleGen
RNA probes, followed by Illumina RNA-Seq
FastQC, Tanoti, in-house resistance mutation tools,
de novo assembly using MetAmos
UCL SureSelect U-Capt SureSelectXT Target Enrichment library preparation
and hybridization and enrichment using custom
designed RNA probes, followed by Illumina
DNA-Seq
Genome mapping,c assembly and finishing using CLC
Genomics Workbench from Qiagen. DAA analysis
using in-house script
PHE Pre-PCR P-PCR Genotype-specific nested PCR of 5 or 6 overlapping
fragments, followed by Illumina sequencing.
Contig assembly by SPAdes 3.5.0. HCV contigs longer
than 250-nt assembled and PCR fragments
combined using Sequencher 5.0. Reads were
remapped to assembled sequences using BWA
0.7.5.
a See reference 10.
b V. Sreenu, G. Nikolov, S. Alotaibi, T. Abdelrahman, K. Brunker, R. Orton, T. Klymenko, G. Wilkie, and E. Thomson, submitted for publication.
c Adapted from reference 17.
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were frequently validated by checking alignments of all publicly available
genome sequences to detect any intragenotype variations; new batches of
primers are validated side by side with old primer stock on samples that
had been previously amplified and sequenced. Primer stocks are also re-
validated every 6 months.
Several measures were in place to prevent and monitor PCR contam-
ination, including the following: (i) inclusion of negative controls within
each batch of extractions and amplifications; (ii) standard PCR work-
flows, such as directional material flow, geographical and temporal sepa-
ration of PCR stages, reagent aliquoting, etc.; (iii) bioinformatic pipeline
that includes the use of a depth threshold of100 (as contaminants rarely
have a depth greater than 10); and (iv) phylogenetic-tree-based contam-
ination checking that includes all sequences within a run and those pro-
cessed on several previously immediate runs.
Bioinformatic processing. (i)Oxford.Asdescribedpreviously (10, 12),
low-quality bases were trimmed from demultiplexed sequences using
QUASR v7.01 (www.bioconductor.org/packages/release/bioc/html
/QuasR.html), and adapter sequences were removed using CutAdapt v1.7.1
(http://cutadapt.readthedocs.io/en/stable/index.html). Human sequences
wereexcludedbymapping to theHG19humanreferencegenomeswithBow-
tie v2.2.4 (http://bowtie-bio.sourceforge.net/index.shtml), andHCV-derived
readswerealigned toa localBLASTdatabaseof165HCVgenomescollatedby
the ICTV (International Committee on the Taxonomy of Viruses). PE reads
were assembled de novo into contiguous whole-genome sequences with
Vicuna v1.3 and finished with V-FAT v1.0 (http://www.broadinstitute
.org/scientific-community/science/projects/viral-genomics/v-fat). Reads
were mapped back to the assembly using Mosaik v2.2.28 (http://gkno.me
/pipelines.html#mosaik), and variants were called by V-Phaser v2.0 (http:
//www.broadinstitute.org/scientific-community/science/projects/viral
-genomics/v-phaser-2).
(ii) Glasgow. Fastq file quality was assessed using FastQC (http://www
.bioinformatics.babraham.ac.uk/projects/fastqc/). Sam files were created
by mapping against 64 whole-genome HCV reference sequences using
Tanoti (http://bioinformatics.cvr.ac.uk/tanoti.php) and de novo assembly
using the MetAmos pipeline (http://www.cbcb.umd.edu/software
/metamos/). Assemblies were viewed using UGene (http://ugene.net/).
Genotype ratios were calculated by a kmer-based approach using kmers
unique to each genotype.
(iii) UCL.Genomemapping, assembly, and finishing were performed
using CLC Genomics Workbench (Qiagen version 7.5/7.5.1). All read
pairs were subject to quality control, and reads were quality trimmed on
the basis of a cutoff average Phred score of 30 and the presence of ambig-
uous nucleotides. Adapter trimming of Illumina-specific adapters was
performed on all samples. Trimmed reads were mapped against a Gen-
Bank reference list containing 953 HCV genomes to identify the best
matching HCV reference. Each sample was mapped using the default
affine gap cost parameters followed by local realignment. Total base
counts at each genomic position were recorded using an in-house script.
(iv) PHE. A subset of the MiSeq PE reads from each FATSQ file was
compared to a local database of 1,684 HCV whole-genome reference se-
quences using BLAST to identify an optimum reference sequence for
mapping and BWA-MEM (v0.7.5) (https://www.msi.umn.edu/sw/bwa).
Utilizing SAMtools (http://samtools.sourceforge.net/mpileup.shtml),
the resulting files were converted into BAM format. In-house software
(QuasiBAM) generated consensus sequences for minority variants. Pro-
cedures were automated using a computational pipeline developed in-
house with Python and C. For detection of multiple HCV genotypes,
FASTQfiles derived from amplification of theNS5B genotyping fragment
were digitally normalized (Kmer software) to reduce the number of du-
plicate reads and assembled (SPAdes v3.5.0; http://bioinf.spbau.ru
/spades). Contigs were compared with a database of NS5B fragments rep-
resenting different HCV genotypes using BLAST and stitched together to
give the longest possible sequence from each genotype detected by the
contig BLAST process. Where multiple genotypes were detected, the con-
tigs were trimmed to match the length of the shortest sequence. The total
population of reads (nonnormalized FASTQ files) were then reference
mapped against the genotype-specific assembly contigs using BWA, and
the proportion of reads mapping to each genotype was calculated using
the statistics programs in the BamTools suite.
(v) Consensus sequence generation. For all methods, a majority base
consensus sequence was calculated at each nucleotide site possessing 10 or
more base reads. A global consensus sequence was generated similarly as a
majority consensus sequence for the seven different sequencing methods.
Any assembled sequence that was5%divergent from those generated by
other NGS methods were discarded.
PCR amplicon sequencing. A genotype 1-specific PCR was used to
amplify sequences in the NS3 and NS5B regions (positions 3288 to 5727
and 7407 to 9366, respectively; total 4,100 bases) from genotype 1a and 1b
panelmembers (n-12). Sanger sequencing used the dideoxy ABI sequenc-
ing systems in both directions using overlapping internal primers (see
Table S2 in the supplemental material). Sequences were analyzed using
Sequencher software (Gene Codes) and aligned using subtype-specific
consensus sequences.
Sequences obtained from each method were compared with those
derived from NGS methods (global consensus), and the numbers of nu-
cleotide and amino acid sequence differences were recorded using the
program Sequence Dist in the SSE package.
RAV analysis. For the RAV analysis, positions of interest were identi-
fied in the GenBank reference hepatitis C strain H77 polyprotein gene,
complete coding sequence (AF011751). Each reference used for mapping
was aligned to the HCV strain H77 reference to standardize the positions
of interest, and the counts for each base were identified at the DAA-
associated positions.
Statistics. Spearman’s rank order correlation test was used to test the
significance of the association between viral load and HCV read counts.
The Kruskal-Wallis nonparametric one-way test of variance was used to
compare detection and assembly of genotype 1/non-genotype 1 HCV
reads. A P value of0.05 was considered significant.
Accession numbers.HCV-specific reads for the 43 samples have been
submitted to the European Nucleotide Archive (ENA) under projects
PRJEB11791 (Oxford). Consensus nucleotide sequences of HCV and hu-
man pegiviruses have been submitted to GenBank and have been assigned
accession numbers KU180708 to KU180731.
RESULTS
HCV read depths and genome coverage.The abilities of different
NGS methods to recover HCV sequences from samples with dif-
ferent viral loads was compared (Fig. 1). Each method was effec-
tive at detecting HCV sequences in most or all panel samples with
a wide range of viral loads, including those as low as 2,000 IU/ml.
There was a significant association between read counts and viral
loads by using both metagenomic and enrichment methods (Fig.
1), but not after PCR preamplification, where similar read num-
bers were obtained over a large viral load range (Fig. 1C). Collec-
tively, enrichment consistently recovered more HCV sequence
reads than metagenomic methods did (Fig. 1D). There was no
evidence for genotype 1 or non-genotype 1 RNA sequences being
preferentially detected by any method (P 0.05).
Reads were assembled by mapping to the closest available ref-
erence sequences or de novo (Table 1), and amultiple alignment of
the assemblies was inferred. Majority rule consensus sequences
were inferred from the reads mapped to the assembly and ana-
lyzed for completeness. Complete genome sequences (95% of
H77 sequence length) were assembled for the majority of samples
by eachmethod (Fig. 2). However, particularly withmetagenomic
methods, only partial assemblies were generated from samples
with lower viral loads. There was no evidence that non-genotype 1
Evaluation of Whole-Genome Sequencing Methods for HCV
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samples were less effectively assembled than genotype 1 samples
for all methods (P 0.05).
Inspection of read depth across each consensus sequence
showed that each method yielded relatively uniform coverage
across the genome (Fig. 3A to C). In general, read depth across the
genome was more uniform for the metagenomic methods (Fig.
3A; also see Fig. S1A in the supplemental material, Z-scores rang-
ing from2 to2). The lowest coverage for all methods were the
5= untranslated regions (5=UTRs) and the region beyond the 3=
poly(U) tract (Fig. S2). No sequences were complete at the 5= and
3= ends as defined by the sequence span of the H77 sequence. PCR
preamplification necessarily limited the coverage of the P-PCR
method to positions of the nested sense primer in 5=UTRs and
3=UTRs. Similarly, the reference sequences used for assembly of
sequence reads in the G-Meta, G-SSel, and G-Nimb methods
lacked the X-tail sequence beyond the polypyrimidine tract and
could not be assembled beyond this point. Only the sequences
generated by O-Meta and O-Capt were assembled in the highly
structured X-tail.
Accuracy of assembled HCV sequences. The genotype of
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FIG 1 Relationship between viral loads and read counts for each method. (A to C) Total HCV-specific bases read from each sample (y axis, log scale) was
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HCV in sequences assembled from each sample was determined
by sequence comparisons with reference HCV strains (Fig. 4; also
see Table S1 in the supplementalmaterial). Genotype assignments
were concordant between NGSmethods and the clinical genotyp-
ing assays. HCV sequences assembled by NGS were analyzed both
by comparison of majority (consensus) sequences and through
within-site variability. Majority sequences generated by different
NGS methods were generally identical or similar to each other
(Fig. 4). However, several assembled sequences failed tomatch the
consensus sequence of other NGS-generated sequences (shown in
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FIG 3 Variability in read depth across the HCV genome coverage and divergence from a global consensus for each of the sequencing methods. (A to C) Mean
read coverage across the HCV genome by different NGSmethods. Mean coverage was calculated as the number of bases at each site as a proportion of total reads
for the sequence (expected mean value of 0.00014); mean values were calculated from samples with100,000 total reads. Genome positions were based on the
H77 reference sequence. A genome diagram of HCV drawn to the same scale as the x axis is included below panels A to C. A plot of Z-scores is provided in the
supplemental material (see Fig. S1 in the supplemental material). (D to F). Divergence between the global consensus and individual consensus sequences
generated by different methods were calculated for a sliding window of 250 bases centered on every 30th base. Mean divergence values for each sequencing
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supplemental material.
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green) even if NGS defined the same subtype. For one sample
(sP799685), four different HCV strains (5% divergent from
each other) were detected by different methods (shown in red).
Samples yielding discrepant sequences were typically those with
low coverage and lower viral loads (Fig. 4, VL-IU/ml column),
particularly the incomplete sequences generated by G-Meta and
G-SSel methods. The PCR methodology for HCV genotype 2 in
particular frequently failed to generate whole genomes. The fol-
lowing sequences were excluded from further analyses of viral
heterogeneity, since the incompleteness of sequence representa-
tion precluded generating an informative sample consensus se-
quence: sP546783, sP371169, sP800022, sP510486, and sP799685.
To analyze the similarity of sequences generated by each NGS
method, the sequences were compared to a global consensus se-
quence, representing the combined consensus of the different se-
quencing methods. Few consensus sequences were identical to
global consensus over the whole genome, with many having 10 or
more differences (Fig. 5A and B). These differences were concen-
trated in the hypervariable regions (hypervariable region 1
[HVR1] [E2], 384 to 410; HVR2 (E2), 473 to 480; V3 [NS5A],
2356 to 2379, H77 coordinates [12]) and surrounding E1 and E2
regions (Fig. 3D to F), and divergence was particularly evident
for genotype 2 samples (see Fig. S3 in the supplemental mate-
rial). Different NGS methods showed similar diversity of se-
quences with the exception of P-PCR, which showed a median
of 12 and 9 nucleotide and amino acid differences, respectively,
from the global consensus over the complete genome (Fig. 5A
and B).
For comparative evaluation of sequencing accuracy with stan-
dard PCR/sequencing methodologies, sequences were amplified
using separate NS3 and NS5B PCRs (positions 3288 to 5727 and
7407 to 9366, respectively; total 4,00 bases) of genotype 1 panel
members (identified in Table S1 in the supplemental material).
Sequences directly obtained by Sanger sequencing from the am-
pliconwere comparedwith the global consensus sequence derived
from NGS (Fig. 5D). Most samples showed sequence identity be-
tween the two methods. Sequence differences between methods
occurred predominantly at polymorphic sites where the base
0% 100%90%
Completeness of sequences matching global consensus
Completeness of sequences not matching global consensus
Completeness of sequences where no global consensus was available
Sequencing Method
Sample Data Whole RNA Target-enriched PCR
Sample VL-IU/ml G-Meta O-Meta G-SSel O-Capt G-Nimb U-Capt P-PCR
sP528652 19256 0% 99% 99% 100% 100% 100% 100%
sP915548 242190 100% 98% 100% 100% 100% 99% 100%
sP883026 1640152 100% 100% 100% 100% 100% 100% 100%
sP824545 195214 100% 100% 100% 100% 100% 100% 100%
sP731482 1447136 98% 98% 98% 99% 99% 100% 100%
sP495677 1782930 100% 100% 100% 100% 100% 99% 100%
sP312482 335842 100% 100% 100% 100% 100% 99% 99%
sP841485 1795374 100% 100% 100% 100% 100% 100% 99%
sP237998 425444 100% 100% 100% 100% 100% 100% 100%
sP256432 877020 100% 100% 100% 100% 100% 99% 100%
sP104509 18214
sP546783 2230 27% 18% 27% 40% 49% 98% 99%
sP643870 402416 100% 100% 100% 100% 88% 100% 100%
sP575531 17838 99% 95% 96% 99% 99% 100% 86%
sP371169 3048 89% 26% 89% 49% 60% 98% 42%
sP800022 10662 99% 85% 100% 98% 100% 0% 99%
sP681788 4559808 100% 100% 100% 100% 100% 100% 81%
sP510486 38072 48% 94% 100% 100% 100% 99% 99%
sP799685 12168 70% 65% 70% 99% 100% 98% 83%
sP260631 29230 100% 100% 100% 100% 99% 100% 99%
sP791266 987104 100% 100% 100% 100% 100% 100% 100%
sP641886 628072 100% 100% 100% 100% 100% 100% 100%
sP759580 468958 100% 100% 100% 100% 100% 100% 100%
sP598047 22754 100% 100% 100% 100% 100% 98% 100%
sP093793 1276834 100% 100% 100% 100% 100% 99% 76%
sP181675 4854384 99% 100% 99% 100% 100% 99% 56%
sP455229 156258 93% 100% 92% 100% 99% 100% 51%
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FIG4 Comparison of the completeness of consensus sequences and their genetic relatedness to each other. Percentage sequence completeness for coding regions
is given for each sample. Consensus sequenceswere assembled from the panel samples by eachNGSmethod andused to defineHCVgenotype and comparedwith
the genotype identified by conventional genotyping assay (Genotype column). Samples have been ranked by viral load (VL-IU/ml column) (from highest to
lowest). Assembled sequences that correspond to the global consensus are shown on a gray/white scale; those that differed by5% in nucleotide sequence from
each other were considered separate strains and are shown on a green scale. Sample sP799685 generated a diverse range of sequences by different NGSmethods,
and it was not possible to generate a global consensus sequence by combining sequences (red shading). NA, not available.
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called in the PCR-derived sequence was represented at various
proportions among NGS sequences but not called in the majority
NGSS consensus sequence (data not shown).
To further determine the accuracy of sequences generated by
NGSmethods, RNA transcripts of HCV genotypes 1a and 2a were
sequenced by representative metagenomic and enrichmentmeth-
ods (O-Meta and O-Capt) to estimate a technical error rate. Se-
quence errors have originated frommisincorporation errors dur-
ing reverse transcription of the RNA sequences, errors during
strand extension during sequencing, and finally bioinformatic er-
rors during base calling and sequence assembly. However, thema-
jority consensus sequences of both transcripts were identical to
those of both original clones by the two methods (Table 2), indi-
cating thatmethods-associated technical errors were not the cause
of sequence differences in consensus sequences of the panel sam-
ples between methods.
For further evidence that the differences between consensus
sequences generated by different methods reflected biological di-
versity, relative frequencies of synonymous and nonsynonymous
substitutions were calculated for the nonstructural gene region
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FIG 5 Assessment of viral diversity: sequence differences between the global consensus and majority sequences generated by each NGS method, and the
association of HCV viral load with diversity. (A and B) Distribution of the numbers of nucleotide and amino acid differences, respectively (y axis, log scale)
between the global consensus sequence and the individualmajority-rule sequences generated by eachNGSmethod (x axis). Sequences phylogenetically unrelated
to the global consensus (shaded green in Fig. 4) or where there was no global consensus (shaded red in Fig. 4) have been excluded from this analysis. Gray bars
represent median values for the distribution. (C) Nonsynonymous/synonymous ratio of substitutions between each assembled sequence and the corresponding
global consensus sequence. More-divergent sequences showing 5 differences (Diffs) from the global consensus are plotted with gray filled circles. (D)
Distribution of nucleotide and amino acid differences between directly sequenced amplicons derived from the NS3 (positions 3288 to 5727) and NS5B region
(positions 7407 to 9366) of 12 samples from the evaluation panel with corresponding regions from the global consensus obtained by NGS methods.
TABLE 2 Error rates of representative sequencing methods for HCV genotype 1a and 2a transcriptsa
Method Transcriptb Unresolved sites (5%)c Shannon entropy at all sites
Shannon entropy at codon position:
1 2 3
O-Meta 1a_AF011751 35 0.0158 0.0150 0.0157 0.0135
2a_AB047639 42 0.0129 0.0132 0.0143 0.0166
O-Capt 1a_AF011751 25 0.0079 0.0077 0.0075 0.0075
2a_AB047639 18 0.0065 0.0065 0.0029 0.0032
a All methods had 100% accuracy for the sequence concordance of majority consensus sequence with the sequence of the clone.
b Transcripts are shown by the HCV genotype first and the GenBank accession number.
c Number of ambiguous sites (discordant reads forming5% of total).
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(Fig. 5C); natural variability typically occurs at synonymous sites
(ratio of nonsynonymous to synonymous evolutionary substitu-
tions [dN/dS ratio] of0.2 in theHCV genome), while variability
arising from technical error associated with the NGS method
would be unbiased (dN/dS ratio of 	1). All sequences showed
dN/dS ratios below 1, with most ratios substantially lower (0.2)
and consistent with naturally occurring variability. To investigate
whether the particularly divergent sequences (5 nucleotide dif-
ferences from the sample consensus) originated from read/assem-
bly errors, they were plotted with a different symbol (gray circles
in Fig. 5C). There was little association between the degree of
sequence divergence and the dN/dS ratio.
Assessment of quasispecies diversity of HCV. The observed
diversity of sequences may originate from naturally occurring
variability of variants within samples (“quasispecies”) or tech-
nical sequencing errors. The contribution of the latter techni-
cal errors to quasispecies diversity was determined though
analysis of base counts at each site of sequences derived from
the RNA transcripts of genotypes 1a and 2a (Table 2). Analysis
of individual base reads at each site revealed that only a small
minority of the	9,500 sites were polymorphic at the 5% level,
ranging from 18 to 42.
This diversity was formally quantified through calculation of
Shannon entropy where at each nucleotide site, 0 represents no
variability, 1 represents equal frequencies of two bases, and 2 rep-
resents equal frequencies of all four bases. Themean values for the
transcripts (0.0065 to 0.0158) were substantially lower than those
observed for RNA sequences present in the panel samples (Table
2; Fig. 6). Variability was evident between sequencing methods,
with less diversity observed for pre-PCR or metagenomic se-
quencing methods. Diversity increased significantly with increas-
ing viral load using metagenomics, but to a much lesser extent
with enrichment (Fig. 6).
Aswith the analysis of sequence differences from the consensus
(previous section), within-population variability should be
greater at 3rd codon positions (where changes are more likely to
be synonymous) if the detected within-site diversity is naturally
generated. This was indeed the case, with 2 to 3 times greater
Shannon entropy values at 3rd codon positions compared to the
1st and 2nd codon positions both over the whole coding region
(Fig. 6D) and in particular if analysis was restricted to the non-
structural gene region (Fig. 6E). As anticipated, no bias toward
greater entropy values at 3rd codon positions was evidence in the
transcript sequence (Table 2).
Detection of mixed genotypes. The ability of different NGS
methods to detect coinfections with more than one genotype
was determined using a panel of plasma samples containing
RNA representing different genotypes in different ratios. These
samples included the two mixed-infection plasma samples dis-
tributed as part of a United Kingdom national quality control
panel (QCMD1 and QCMD2), five plasma samples generated
from a mixture of component plasma samples with measured
viral loads and calculated ratios (sP731482, sP104509, and JW1
to JW3), a series of RNA transcripts of genotypes 1a and 2a in a
wider range of ratios (IVT1 to IVT5 [see Table S1B in the
supplemental material]).
The reads from each sequencing method were processed using
an appropriate bioinformatic pipeline developed by the expert
center (Table 1) to infer the genotype and consensus sequence for
up to two populations of reads in each sample. The ratios of reads
were compared to those of input RNA copies (Fig. 7). For all
methods, there was a close and reproducible relationship between
the input proportions of plasma and transcript sequences of dif-
ferent genotypes and the relative frequencies of reads byNGS. The
majority of observed ratios fell close to the x
 y line added to each
graph.
DAA resistance mutation detection. Frequencies of naturally
occurring RAVs in NS3, NS5A, and NS5B genes were compared
between the sequencing methods for samples in the evaluation
panel; all subjects were DAA treatment naive at the time of sample
collection (Fig. 8). Potential RAVs were most frequently detected
in the NS3 and NS5A genes, particularly in non-genotype 1 se-
quences, with highly infrequent detection of resistance at sites
associated with inhibitors of the NS5B polymerase (e.g., S282 and
L419). Several RAVs were found as majority variants (such as
the NS3 Q80K mutation in genotype 1a strains; Fig. 8), and
these were consistently detected by different sequencing meth-
ods. However, methods varied considerably in their detection
of minor populations of RAVs (shown in yellow), with several
inconsistencies in their detection or percentage population
representations. In general, Glasgow metagenomic and both
Glasgow and Oxford capture methods recorded highest fre-
quencies of minor populations of RAVs in all three genes, but
in many cases, different polymorphic sites were identified in
different samples.
Coinfecting viruses.Metagenomic sequence libraries gener-
ated by G-Meta and O-Meta were screened by blastn for other
human viruses using example sequences obtained from RefSeq
(NCBI). Of the 6,783 human viruses screened (NCBI RefSeq
viruses r63 [ftp://ftp.ncbi.nlm.nih.gov/refseq/release/viral/]),
three samples contained some human pegivirus (HPgV) se-
quences. One sample, from patient sP104509, could be assem-
bled into a single contig with 100% coverage of the reference
and high-read depth (1,600 for O-Meta), and virtually identical
assemblies were derived via the O-Meta and G-Meta methods.
DISCUSSION
Whole-genome sequencing of HCV from clinical samples has un-
til now been considered a costly, laborious, and technically chal-
lenging procedure that has not been adopted in routine clinical
practice. The major challenge to conventional PCR Sanger se-
quencing is the inherent diversity of the virus that limits the degree
of primer match with different strains and genotypes, generating
consensus sequences of limited value and often failing to generate
amplicons for large parts of the genome. In contrast, NGS tech-
nologies have the potential to generate full-length HCV genomic
sequences that enable (i) accurate inference of the full-length,ma-
jority consensus HCV genome in the sample and the detection of
(ii) minor circulating viral populations within individuals, (iii)
mixed-geno(sub)type infections, and (iv) the presence of treat-
ment-associated RAVs along the entire genome. All four metrics
will inform future treatment decisions in the new era of DAA
therapies.
In order to compare and measure the consistency of different
approaches, we evaluated three NGS methodologies, including
metagenomic sequencing, target enrichment using bothDNAand
RNA oligonucleotide probes, and the generation of multiple am-
plicons by PCR before NGS. For this, we used clinical samples
containing a single genotype or amixture of different genotypes or
subtypes across a range of HCV viral loads. All NGS methodolo-
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gies were able to generate whole genomes from clinical samples
and more accurately defined the HCV subtype than the probe-
based assay that is commonly used in clinical practice. However,
we identified clear advantages and disadvantages to each. The
metagenomic approach is fundamentally attractive, since this
technique has the capacity to detect other pathogens that may
be clinically relevant, and stored metagenomic data can be uti-
lized for viral discovery; as proof of principle, we were able to
recover complete HPgV genome sequences in clinical HCV
samples using this approach. However, metagenomics pro-
vided significantly lower depth of coverage than other method-
ologies and performed less well at lower HCV viral loads in
generating WGS. Furthermore, this approach was relatively
costly for the numbers of HCV reads generated, since the vast
majority of reads obtained were of human origin and were
discarded.
NGS that relies on PCR amplification is currently utilized for
the detection of viral resistance. However, in our experience, de-
veloping full-length sequences using this approach for even a
small number of patients was relatively laborious, requiring mul-
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and the nonstructural regions (E).
Thomson et al.
2480 jcm.asm.org October 2016 Volume 54 Number 10Journal of Clinical Microbiology
 o
n
 O
ctober 28, 2016 by SW
ETS SUBSCRIPTIO
N SERVICE
http://jcm.asm.org/
D
ow
nloaded from
 
tiple PCRs per sample, compared to a single library per sample for
metagenomics and the subsequent pooling of 96 libraries in a
single tube for sequence capture. It was therefore less suited in its
current stage of development for high-throughput analysis. Fur-
thermore, prior knowledge of viral genotype was required; the
failure to generate HCV amplicons was particularly evident for
HCV genotype 2, since there are currently relatively few complete
genome sequences for this genotype available to inform primer
design. A linear relationship between HCV viral load and the
number of HCV reads was observed with both metagenomic and
target enrichment sequencing, but not PCR preamplification
where similar numbers of HCV reads were obtained irrespective
of viral load. Amplification of viral sequences prior to NGS is
therefore likely to be of particular value for samples with lowHCV
viral loads.
Variability in coverage and sequencing depth across the ge-
nome was observed with all methods. This may originate
through variability in the degree of match between probe or
primer sets to the target viral sequence and therefore differ-
ences in the efficiency of target capture or amplification. We
have recently shown that introducing probes to better repre-
sent known sequence variation can reduce bias in coverage due
to probe-target divergence to zero (10). However, incomplete
coverage was not a consistent problem for any of the capture
methods, which in fact provided substantially greater depth of
HCV coverage than metagenomic methods that were probe
independent. Capture methods, overall, were better able to
generate WGS for the same sequencing effort across a wide
range of HCV viral loads.
Overall, there was concordance in the HCV genotypes identi-
fied by all NGS methods at each center. While the majority of
consensus sequences obtained by each sequencing center were
identical to each other, unrelated sequences were obtained in a
minority of cases; this could be explained by sequencing error,
cross-contamination, or preferential sequencing of one strain
over another in samples from patients with mixed-strain infec-
tion. Sequencing error was considered unlikely to have contrib-
uted significantly to these differences, as the dN/dS ratio was con-
sistently low with an increase in variability at the 3rd codon site
(usually a synonymous position) in keeping with natural occur-
ring variability. Furthermore, NGS of RNA transcripts demon-
strated extremely low frequencies of sequencing errors from a
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FIG 7 Capacity of NGS to detect mixed-genotype/subtype samples. Observed ratios of NGS read counts between component genotypes genotype A (Gt A) and
genotype B (Gt B) (y axis) compared to their input ratios (x axis), plotted on a log/log scale. The dotted line represents the expected position of data points if the
assays were able to detect both input genotypes (genotypes A and B) with equal efficiency. Samples of mixed genotype of known ratio (the input ratio) were
acquired from QCMD or through patient samples or in vitro transcripts of known genotype that were mixed in vitro (listed in Table S1B in the supplemental
material).
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defined template, while NGS-derived sequences differed little
from Sanger-sequenced amplicons from the NS3 and NS5A/5B
regions (Fig. 5D).
Infection with mixed HCV genotypes has been frequently
reported (13–15), but its true incidence is unknown, since ex-
isting genotyping assays are not designed to assess this. The
impact on clinical care of mixed-genotype infections is not yet
clear, but theoretically, more drug-resistant genotypes such as
genotype 3 could result in treatment failure as a result of
emerging dominance during treatment (16). NGS methodolo-
gies that routinely captured this data would therefore represent
an important advance. For all methodologies, we demon-
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sP528652 1a 0% 0% 0% 0% X 0% 0%
sP915548 1a 0% 0% 0% 0% 0% 0% 0%
sP883026 1a V->A 0.40% 0% 0% 0.01% 0% 1.0% 0.08%
sP824545 1a V->A 1.0% 0% 0% 0.01% 0% 0.21% 0%
sP731482 1a 0% 0% 0% 0% 0% 0% 0%
sP495677 1a X X 0% 0% 0% 0% 0%
sP312482 1a 0% 0% 0% 0% 0% 0% X
sP841485 1a X X 0% 0% 0% 0% X
sP237998 1a 0% 0% 0% 0% 0% 0% 0%
sP256432 1a 0% 0% 0% 0% 0% 0% 0%
sP104509 1b V->L 0% X 0% 0% X 0.40% 3.5%
sP546783 1b 0% 0% 0% 0% 0% 0% 0%
sP643870 1b 0% 0% 0% 0% 0% 0% 0%
sP575531 1b 0% 0% 0% 0% 0% 0% 0%
sP371169 1b 0% X X 0% 0% 0% 0%
sP455229 1b V->G 4.2% 0% X 0% 0% 0.06% 0.18%
sP800022 2a X X X 0% 0% X X
sP681788 2b 0% 0% 0% 0% 0% 0% 0%
sP510486 2b 0% 0% 0% 0% X 0% 0%
sP799685 2b 0% 0% 0% 0% 0% 0% 0%
sP260631 3a 0% X 0% 0% 0% X X
sP791266 3a 0% 0% 0% 0% 0% 0% X
sP641886 3a X X 0% 0% 0% 0% X
sP759580 3a 0% X 0% 0% 0% 0% X
sP598047 3a 0% 0% 0% 0% X 0% 0%
sP093793 4a 0% 0% 0% 0% 0% 0% 0%
sP181675 4d 0% 0% 0% 0% 0% 0% 0%
Q->K 0% 0% 0% 0.05% X 1.7% 0.55%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
Q->K 99% 98% 100% 100% 100% 98% 99%
Q->K 1.7% 0% 0% 0.04% 0% 0.86% 0.21%
Q->K X X 0% 0.09% 0% 3.8% 0.26%
Q->K 2.1% 1.4% 0% 0.01% 0.37% 1.6% X
Q->K X X 0% 0% X 35% X
Q->K 98% 99% 100% 100% X 99% 99%
0% 0% 0% 0% 0% 0% 0%
0% X 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
Q->K 3.6% 0% 0% 0.01% 0.18% 0.13% 0.10%
0% X X 0% 0% 0% 0%
0% 0% X 0% 0% 0% 0%
X X X 0% 0% X 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% X 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% X 0% 0% X X X
X 0% 0% 0% 0% 0% X
X X 0% 0% 0% 0% X
0% X 0% 0% 0% 0% X
0% 0% 0% 0% 0% 0% 0%
Q->K 1.2% 0% 0% 0% 0% 0.05% 0.14%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% X 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
X X 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
X X 0% 0% X 0% X
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
T->A 0% 0% 0% 0% 0% 1.6% 0.10%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
T->A 0% 1.1% 1.6% 0.01% 0% 0.38% 0.49%
0% X X 0% 0% 0% 0%
0% 0% X 0% 0% 0% 0%
X X X 0% 0% X X
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% X 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% X 0% 0% X X X
X 0% 0% 0% 0% 0% X
X X 0% 0% 0% 0% X
0% X 0% 0% 0% 0% X
0% 0% 0% 0% X 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% X 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
F->S 0% 0% 0% 0.01% 4.2% 2.9% 4.9%
X X 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% X
X X 0% 0% X 0% X
0% 0% 0% 0% 0% 0% 0%
F->S 2.3% 0.99% 0% 0.08% 0% 0.15% 0.03%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% X X 0% 0% 0% 0%
0% 0% X 0% 0% 0% 0%
X X X 0% 0% X X
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% X 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% X 0% 0% 0% X X
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X X 0% 0% 0% 0% X
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0% X 0% 0% X 0% 0%
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0% 0% 0% 0% 0% 0% 0%
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0% X 0% 0% 0% 0% 0%
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0% X 0% 0% X 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% X 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% X X 0% 0% 0% 0%
0% 0% X 0% X 0% 0%
X X 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% X 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% X 0% 0% X 0% X
X X 0% 0% 0% 0% X
X X 0% 0% 0% 0% X
0% X 0% 0% 0% 0% X
0% 0% 0% 0% X 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% X 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% X 0% 0% 0% 0% 0%
D->G 0% 1.2% 0% 0.01% 0.44% 0.26% 0%
0% X 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% X 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% X X 0% 0% 0% 0%
0% 0% X 0% X 0% 0%
X X 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% X 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% X 0% 0% X 0% X
D->Q X X 100% 100% 98% 100% X
D->Q X X 100% X 100% 99% X
D->Q 100% X 100% 100% 95% 100% X
D->Q X X 100% 100% X 100% 100%
0% 0% 0% 0% 0% 0% 0%
D->E 0% 0% 0% 0% 0% 0.02% 1.5%
sP915548 1a S->R 0% X 0% 0% X 0.21% 1.1%
sP824545 1a 0% 0% 0% 0% 0% 0% 0%
sP495677 1a 0% 0% 0% 0% 0% 0% 0%
sP237998 1a 0% 0% 0% 0% 0% 0% 0%
sP256432 1a 0% 0% 0% 0% 0% 0% 0%
sP104509 1a X X 0% 0% 0% 0% 0%
sP643870 1a 0% 0% 0% 0% 0% 0% 0%
sP799685 1a 0% X 0% 0% 0% 0% 0%
sP641886 1a S->R 0.36% 0% 0% 0% 0% 0.20% 1.5%
sP759580 1a S->R 0% 0% 0% 0% 0% 0.16% 1.2%
sP528652 1b 0% X 0% 0% 0% 0% 0%
sP883026 1b 0% 0% 0% 0% 0% 0% 0%
sP841485 1b 0% 0% 0% 0% 0% 0% 0%
sP791266 1b S->R 0% 0% 0% 0% 0% 0.26% 1.8%
sP598047 1b S->R X X X 0% 0% 0.95% 3.1%
sP455229 1b 0% 0% X 0% 0% 0% 0%
sP371169 2a X X 0% 0% 0% 0% X
sP681788 2b S->R 99% 100% 100% 100% 100% 100% 100%
sP093793 2b S->R 100% 99% 100% 100% X 100% 99%
sP181675 2b S->R 100% 100% 100% 100% 100% 100% 100%
sP546783 3a 0% X 0% 0% X 0% X
sP575531 3a X X 0% 0% 0% 0% X
sP800022 3a X X 0% 0% 0% 0% X
sP510486 3a 0% X 0% 0% 0% 0% X
sP260631 3a 0% 0% 0% 0% X 0% 0%
sP731482 4a 0% 0% 0% 0% 0% 0% 0%
sP312482 4d 0% 0% 0% 0% 0% 0% 0%
S->G 0% X 0% 0.07% 0% 1.7% 1.2%
S->N 1.9% 0% 0% 0% 0% 0% 0.65%
0% 0% 0% 0% 0% 0% 0%
S->G,N 1.3% 2.9% 1.6% 1.1% 2.7% 0.84% 10%
0% 0% 0% 0% 0% 0% 0%
S->G X X 1.1% 0% 0% 1.3% 0%
0% 0% 0% 0% 0% 0% 0%
0% X 0% 0% 0% 0% 0%
S->G,N 0% 0% 0% 0.22% 0% 1.8% 3.3%
S->N 0% 0% 0% 0% 0% 0.32% 4.0%
S->N 0% X 0% 0.18% 0% 0.86% 3.3%
S->N 1.6% 0.84% 0% 0.04% 0% 0.11% 1.5%
S->N 2.9% 6.5% 9.9% 3.1% 3.2% 4.7% 7.0%
S->N 1.1% 0.69% 0% 0% 0% 0.26% 2.8%
S->N X X X 0% 0% 1.9% 5.4%
0% 0% X 0% 0% 0% 0%
X X 0% 0% 0% 0% X
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% X 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% X 0% 0% X 0% X
X X 0% 0% 0% 0% X
S->K X X 100% 100% X X X
0% X 0% 0% 0% 0% X
0% 0% 0% 0% X 0% 0%
S->T 99% 99% 100% 100% 99% 99% 99%
S->T 100% 100% 100% 100% 100% 99% 100%
A
FIG 8 Frequencies of RAVs in the study samples (untreated subjects). Frequencies of resistance-associated mutations in NS3 genes (A) and NS5A and NS5B
genes (B) detected by different sequencing methods, shown on a gray or color background to indicate frequencies. Resistance mutations were present either as
minor variants (around 1 to 10% of the population; shown by yellow background) or represented the predominant variant in the population (shown by red
background). Frequency information from samples with10 reads at a site were excluded, as were polymorphisms foundwithin a single sequence. Samples have
been grouped by genotype.
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strated that NGS was remarkably accurate in determining the
ratio of mixed genotypes in clinical samples. In addition to
genotyping, we assessed the presence or absence of resistance
mutations within NS3, NS5A, and NS5B using each sequencing
method. Majority variants were reliably detected by all meth-
ods, but variation was noted in minority variant detection.
Both these data and the mixed-genotype experimental data
suggest that the detection of minority variants is less reliable at
lower ratios.
In summary, we provide a comprehensive analysis of three
NGS sequencing methodologies for the generation of full-length
HCV genomes. Our data suggest that HCV target enrichment is
highly effective, suitable for high-throughput analysis, and rela-
tively effective at low viral loads, generating deep coverage along
the HCV genome. The metagenomic approach remains attractive
because the libraries generated may be probed for additional
pathogens that may contribute to disease development and which
will provide a rich data set for future research endeavors in patho-
gen discovery. PCR preamplification is relatively laborious but
may still have a role in samples with very low viral loads. We have
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sP915548 1a Q->R 0% 0% 0.11% 0% 1.9% 0%
sP824545 1a Q->R 1.9% 0% 0% 0.03% 0.55% 1.0% 0.03%
sP495677 1a 0% 0% 0% 0% 0% 0% 0%
sP237998 1a 0% 0% 0% 0% 0% 0% 0%
sP256432 1a 0% 0% 0% 0% 0% 0% 0%
sP104509 1a Q->R 0% 0% 0.03% 0% 4.1% 1.6%
sP643870 1a 0% 0% 0% 0% 0% 0% X
sP799685 1a Q->R 0% 0% 0.82% X 12% 0%
sP641886 1a 0% 0% 0% 0% 0% 0% 0%
sP759580 1a 0% 0% 0% 0% 0% 0% 0%
sP528652 1b Q->R 80% 100% 100% 100% 100% 99% 100%
sP883026 1b Q->R 99% 100% 100% 100% 100% 100% 100%
sP841485 1b Q->R 100% 100% 100% 100% 100% 99% 100%
sP791266 1b Q->R 99% 100% 100% 100% 100% 87% 100%
sP598047 1b Q->R 100% 100% X 100% 100% 97% 100%
sP455229 1b Q->R 100% 100% X 100% X 100% 100%
sP371169 2a X X X 0% 0% 0% 0%
sP681788 2b 0% 0% 0% 0% 0% 0% 0%
sP093793 2b 0% 0% 0% 0% X 0% 0%
sP181675 2b 0% 0% X 0% 0% 0% 0%
sP546783 3a X X 0% 0% 0% X X
sP575531 3a 0% X X 0% 0% 0% X
sP800022 3a 0% X 0% 0% 0% 0% X
sP510486 3a 0% X 0% 0% 0% 0% X
sP260631 3a 0% 0% 0% 0% X 0% 0%
sP731482 4a Q->R 100% 100% 100% 0% 100% 100% 100%
sP312482 4d Q->R 100% 100% 100% 100% 100% 98% 99%
0% X 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% X 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% X
0% X 0% 0% X 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
L->M 1.7% 0.36% 0% 0% 0.05% 0.05% 0.73%
0% 0% X 0% 0% 0% 0%
L->M 0% 0% X 0% X 0% 1.4%
L->M X X 100% X 100% 99%
L->M 0.12% 0.10% 0% 0.77% 0.83% 3.5% 1.3%
L->M 99% 100% 100% 100% X 99% 98%
L->M 0.16% 0% X 0% 0% 1.1% 0.25%
X X 0% 0% 0% X X
0% X X 0% 0% 0% X
0% X 0% 0% 0% 0% X
0% X 0% 0% 0% 0% X
0% 0% 0% 0% X 0% 0%
L->M 99% 100% 98% X 100% 100% 100%
L->M 97% 100% 100% 99% 100% 99% 99%
0% X 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
Y->H 1.1% 0% 0% 0% 0% 0.14% 0.02%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
Y->H 0% 0% 0% 0% 1.2% 1.4%
Y->H 1.6% 0% 0% 0.01% 0% 0.17% X
Y->H 0% 0% 0% 0% 2.9% 0%
0% 0% 0% 0% 0% 0% 0%
Y->H 1.0% 0% 0% 0% 0% 0.02% 0%
X X 0% 0% 0% 0% 0%
Y->H 99% 100% 100% 99% 99% 98% 100%
Y->H 0.95% 0% 0% 0.23% 0.23% 1.4% 0.10%
Y->H 0% 0.47% 0% 0.03% 0.10% 1.5% 0.15%
Y->H 0% X 0% 3.7% 1.1% 0.04%
Y->S 0% 0% X 0% 0% 0% 2.2%
X X X 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
Y->S 0.70% 0% 0% 0% X 0.02% 1.6%
Y->S 0.35% 0% X 0% 0.23% 0.06% 1.1%
X X 0% 0% X X X
0% X X 0% 0% 0% X
0% X 0% 0% 0% 0% X
Y->H 11% 0% 0.88% 0% 0.60% X
0% X 0% 0% X 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
sP915548 1a 0% X 0% 0% 0% 0% 0%
sP824545 1a S->T 2.7% 7.7% 0% 0% 0% 0.07% 0.06%
sP495677 1a 0% 0% 0% 0% 0% 0% 0%
sP237998 1a 0% 0% 0% 0% 0% 0% 0%
sP256432 1a 0% 0% 0% 0% 0% 0% 0%
sP104509 1a X X X 0% 0% 0% 0%
sP643870 1a 0% 0% 0% 0% 0% 0% 0%
sP799685 1a 0% X 0% 0% 0% 0% 0%
sP641886 1a 0% 0% 0% 0% 0% 0% 0%
sP759580 1a 0% 0% 0% 0% 0% 0% 0%
sP528652 1b 0% X 0% 0% 0% 0% 0%
sP883026 1b 0% 0% 0% 0% 0% 0% 0%
sP841485 1b 0% 0% 0% 0% 0% 0% 0%
sP791266 1b 0% 0% 0% 0% 0% 0% 0%
sP598047 1b 0% X X 0% 0% 0% 0%
sP455229 1b 0% 0% X 0% 0% 0% X
sP371169 2a X X X 0% 0% 0% 0%
sP681788 2b 0% 0% X 0% 0% 0% 0%
sP093793 2b 0% 0% X 0% X 0% 0%
sP181675 2b 0% 0% X 0% 0% 0% 0%
sP546783 3a 0% X 0% 0% 0% 0% X
sP575531 3a X 0% 0% 0% 0% 0% X
sP800022 3a 0% X 0% 0% 0% 0% X
sP510486 3a 0% X 0% 0% 0% 0% X
sP260631 3a 0% X 0% 0% X 0% 0%
sP731482 4a 0% 0% 0% 0% 0% 0% 0%
sP312482 4d 0% 0% 0% 0% 0% 0% 0%
0% X 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% X X 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% X
0% X 0% 0% 0% 0% X
C->N 0.4% 0% 0% 0% 100% 0.1% 0.1%
C->N 0% 0% 0% 0% 0.1% 1.3% 0.2%
C->N 60% 100% 99% 100% 100% 100%
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C->N 0% 0% 0% 0% 0.1% 1.3% 0.2%
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0% X 0% 0% 0% 0% X
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0% X X 0% 0% X 0%
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X X 0% 0% X 0% X
X X 0% 0% 0% 0% 0%
X X 0% 0% 0% 0% 0%
0% X 0% 0% 0% 0% 0%
L->S 0% 0% 0% 0% 0% 0% 1.2%
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FIG 8 (Continued)
Evaluation of Whole-Genome Sequencing Methods for HCV
October 2016 Volume 54 Number 10 jcm.asm.org 2483Journal of Clinical Microbiology
 o
n
 O
ctober 28, 2016 by SW
ETS SUBSCRIPTIO
N SERVICE
http://jcm.asm.org/
D
ow
nloaded from
 
shown thatWGSofHCV is readily achievable acrossmultiple sites
in the United Kingdom. In the era of DAA therapy, where a single
course of therapy routinely costs £30,000, we believe that NGS
for the generation of WGS that accurately defines viral genotype,
and readily detects both RAVs and mixed infections should be
routinely employed. Sequencing by any of the methods evaluated
in the current study can be achieved at a cost of approximately
£120/sample, comparable to that of the existing clinical genotyp-
ing assays. The generation ofWGS for HCV nationwide would be
hugely informative, guiding clinical practice while concurrently
providing an invaluable data set for epidemiology studies and fu-
ture research.
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